BPC
BPC-157
A synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, described as a partial sequence of a protein isolated from human gastric juice. No receptor target for it has been established in the published literature, so no mechanism is stated here. The blank is the finding, not an omission.
BPC-157 has 2 registered human studies on ClinicalTrials.gov, reaching phase 2, covering 162 planned or enrolled participants across the 2 studies that published a figure. No FDA-approved product contains BPC-157. 117 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names BPC-157; the registry search is fuzzy, so every match is re-checked. None of this says whether BPC-157 works or is safe.
FDA status
Research only
Human studies
2
Furthest phase
Phase 2
Papers, 10 yr
117
Readership
31,331
monthly average, Feb–Jun 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Phase 1 or 2 only
2
Registered human studies
Phase 2
Furthest phase reached
162
Planned or enrolled participants, across 2 studies that published a figure
None
No FDA-approved product contains it
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What BPC-157 is, and what it has been studied for
BPC-157 is classified by ChEMBL as a protein, and appears in trial registrations under PL-10 and PL-14736. Its FDA substance identifier is 8ED8NXK95P.
Across 2 registered trials, it has been studied in Healthy Volunteers, Hamstring Muscle Strain and Skeletal Muscle Injury. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by PharmaCotherapia d.o.o. and Hudson Biotech. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
BPC-157 reached Phase 2 across 2 registered trials.
No FDA-approved product contains BPC-157. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying BPC-157?
Papers published each year that name BPC-157 in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 11 | 0 | Yes |
| 2018 | 8 | 0 | Yes |
| 2019 | 5 | 0 | Yes |
| 2020 | 12 | 0 | Yes |
| 2021 | 19 | 0 | Yes |
| 2022 | 13 | 0 | Yes |
| 2023 | 10 | 0 | Yes |
| 2024 | 7 | 0 | Yes |
| 2025 | 16 | 0 | Yes |
| 2026 | 20 | 1 | No |
117 papers and 1 registered trials between 2017 and 2026. A paper counts when “BPC 157” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on BPC-157
117 indexed papers name BPC-157 in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
- BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Collected 2026-08-02from PubMed, phrase-matched on “BPC 157” in title and abstract. Run the same search.
About BPC-157
A synthetic 15-amino-acid peptide, sequence GEPPPGKPADDAGLV, described as a partial sequence of a protein isolated from human gastric juice. No receptor target for it has been established in the published literature, so no mechanism is stated here. The blank is the finding, not an omission.
- Also known as
- PL 14736 · Body protection compound 157
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.